JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy

Details
By J. Smith
J. Smith
About
Last Updated: 28 July 2025
Hits: 920
  • Type 2 Diabetes
  • Obesity Care
  • Diabetes Advocacy
  • Health Data Insights
  • Patient Empowerment

About

At JCS/T2D, we believe that understanding is the first step to action. By exploring the realities of type 2 diabetes and obesity care, we uncover insights that help change how people think—and talk—about these conditions.

Who We Are

We are advocates.
We learn. We share. We inform.
We change the conversation.

Drawing from a strong foundation in data analysis and real-world experience, we focus on bringing clarity to diabetes and obesity care. Our work bridges the gap between research, lived experience, and public understanding—helping to correct misconceptions and highlight what’s possible.

What We Do

We explore the intersection of data and health, uncovering patterns that matter. Our insights are grounded in evidence, shaped by experience, and aimed at supporting more informed, compassionate care.

Why It Matters

Too often, type 2 diabetes and obesity are framed around blame and restriction. At JCS/T2D, we shift the focus toward progress, possibilities, and real-world strategies that empower individuals and support better outcomes.

More Than Advocacy

At JCS/T2D, we bring together advocacy, analysis, and connection.
We turn data into understanding—and understanding into action.

JCS/T2D is part of JCS Analytics, where data-driven insight supports meaningful change.

Why Novo Nordisk Appears Frequently in My Work

Novo Nordisk is mentioned often in my writing. Not out of preference, but because they make significantly more materials available for public use than many of their peers. They publish high-quality educational content, maintain an open media library, and share frequent updates.

In Denmark, there is also a strong culture of collaboration between Novo Nordisk, the University of Copenhagen, and other academic and healthcare institutions, many of whom actively engage with the public. This openness creates more opportunities to responsibly analyze trends, share insights, and clarify complex topics. When other companies provide similar access, I'll give them equal attention.

Our Ethos

Clarity begins where certainty ends.

This mindset shapes how we approach data, complexity, and decision-making.
It’s not just how we work—it’s who we are.

We value thoughtful inquiry over quick answers, knowing that uncertainty often signals the start of real learning.
We believe discovery requires structure, collaboration, and the courage to explore the unknown.
And we approach our work with care, because the stakes are real.

Read the full Ethos

Articles

  • Data Analytics for Type 2 Diabetes
  • Exploring the Neuroprotective Potential of GLP-1: A New Frontier in Medical Research
  • Walking Your Way to Better Blood Sugar Control
  • GLP-1 Receptor Agonists: A New Hope for Obstructive Sleep Apnea and Chronic Kidney Disease
  • Tirzepatide and the Future of Incretin Therapies: A New Horizon in Obesity Treatment
  • Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research
  • New Research Reveals the Hidden Complexity of Insulin Resistance
  • Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
  • GLP-1 RAs and Gastroparesis (Stomach Paralysis)
  • Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss
  • Mounjaro: A New Player in the GLP-1 Arena for Type 2 Diabetes Management
  • Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease
  • Eli Lilly’s Tirzepatide Shows Promising Results in MASH Treatment
  • The Mounjaro Supply Challenges: Looking Back and Looking Forward
  • Understanding and Addressing the Stigma Faced by People with Type 2 Diabetes and Obesity
  • Types of Diabetes
  • Exploring the Potential of Tirzepatide for Obstructive Sleep Apnea: A New Horizon in Treatment
  • Understanding the Link Between Type 2 Diabetes and Chronic Kidney Disease
  • The Future of Type 2 Diabetes and Obesity Care: The Role of DNA Sequencing
  • From Lab to Pharmacy: Navigating the Clinical Drug Trials and Approval Process in the US and EU

News

October 2025

  • FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
  • Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
  • Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
  • Semaglutide’s Heart Benefits Extend Beyond Weight Loss
  • Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

  • CVS Caremark Faces Lawsuit Over Dropping Zepbound
  • Dexcom Introduces Smart Basal at EASD 2025
  • Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
  • Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
  • Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
  • Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
  • Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

  • FDA Approves Wegovy for MASH Treatment
  • FDA Expands Repatha Access to More High-Risk Adults
  • Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
  • Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
  • Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
  • Signos Press Release Raises Questions About FDA Clearance Claims
  • Teva Launches First Generic GLP-1 for Obesity
  • Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

  • Type 2 Diabetes
  • Novo Nordisk
  • Semaglutide
  • Obesity Treatment
  • GLP-1
  • Wegovy
  • Eli Lilly
  • Tirzepatide
  • Ozempic
  • Zepbound
  • Diabetes
  • Obesity
  • FDA Approval
  • Diabetes Management
  • Cardiovascular Health
  • Mounjaro
  • SELECT Trial
  • Continuous Glucose Monitoring
  • GLP-1 Therapy
  • Obesity Management
  • Metabolic Health
  • Orforglipron
  • Disease Modification
  • Dexcom
  • CGM
  • Rybelsus
  • Clinical Trials
  • Oral Semaglutide
  • FDA
  • Diabetes Treatment

Contact Us

Search

5K@ADA

5K@EASD

World Obesity Day

Rochen Web Hosting

Bluesky Social

  • You are here:  
  • Home
  • About
  • About
 
Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.